Send to:

Choose Destination
See comment in PubMed Commons below
Trends Immunol. 2004 Dec;25(12):632-6.

New directions in MS therapeutics: vehicles of hope.

Author information

  • 1The Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Lerner School of Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, U-10, Cleveland, OH 44195, USA.


Basic immunological research has greatly expanded our understanding of the suspected immunopathology of multiple sclerosis (MS) and, more importantly, spawned a new generation of clinical trials evaluating dozens of immune-based therapies. Adhesion molecules are the furthest into development, although patient acceptance and neutralizing antibodies both support the development of small, orally available molecules. Progressive MS probably has a significant neurodegenerative component, so progress with neuroprotective strategies will require appropriate animal models, as well as more advanced clinical imaging techniques, such as brain atrophy and diffusion tensor. Dozens of therapies are in various stages of clinical development and results from these clinical studies will provide important tests of immune and inflammatory mechanisms of MS disease.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk